Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

S14 Ep5: Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD

15:06
 
Share
 

Manage episode 504091115 series 2395115
Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In today’s episode, supported by Sumitomo, we spoke with Tanya B. Dorff, MD, about the use of androgen deprivation therapy (ADT) in patients with prostate cancer. Dr Dorff is section chief of the Genitourinary Disease Program, as well as a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California.
In our conversation, Dr Dorff discussed the role of ADT in prostate cancer management, highlighting where this class of agents fits into National Comprehensive Cancer Network guidelines and how this class has evolved with the development of LHRH antagonists and agonists. She explained how the observational OPTYX study (NCT05467176), a registry of relugolix (Orgovyx) use, aims to address safety and efficacy in combination with androgen receptor pathway inhibitors in patients with advanced prostate cancer. She also noted how early data from OPTYX presented at the 2025 ASCO Annual Meeting showed relugolix's use in localized and metastatic settings. Dorff also talked through relugolix's safety profile, particularly regarding cardiovascular risk, as well as the quality-of-life effects associated with ADT. She also addressed strategies to mitigate financial toxicity, along with the potential for future ADT-sparing treatments.
  continue reading

672 episodes

Artwork
iconShare
 
Manage episode 504091115 series 2395115
Content provided by Audioboom and OncLive® On Air. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and OncLive® On Air or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In today’s episode, supported by Sumitomo, we spoke with Tanya B. Dorff, MD, about the use of androgen deprivation therapy (ADT) in patients with prostate cancer. Dr Dorff is section chief of the Genitourinary Disease Program, as well as a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California.
In our conversation, Dr Dorff discussed the role of ADT in prostate cancer management, highlighting where this class of agents fits into National Comprehensive Cancer Network guidelines and how this class has evolved with the development of LHRH antagonists and agonists. She explained how the observational OPTYX study (NCT05467176), a registry of relugolix (Orgovyx) use, aims to address safety and efficacy in combination with androgen receptor pathway inhibitors in patients with advanced prostate cancer. She also noted how early data from OPTYX presented at the 2025 ASCO Annual Meeting showed relugolix's use in localized and metastatic settings. Dorff also talked through relugolix's safety profile, particularly regarding cardiovascular risk, as well as the quality-of-life effects associated with ADT. She also addressed strategies to mitigate financial toxicity, along with the potential for future ADT-sparing treatments.
  continue reading

672 episodes

ทุกตอน

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play